Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYBRID2: Inhaled hydrogen for neurological outcome after out-of-hospital cardiac arrest
jRCTs031180352Completed
- Sponsor
- Taiyo Nippon Sanso
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Molecular hydrogen in post-cardiac arrest syndrome (PCAS) and brain ischemia (2 arms), sponsored by Taiyo Nippon Sanso. Primary endpoint: Favorable neurological outcome at 90 days. Started Mar 2017; status: completed.
02
Drugs
Molecular hydrogen
03
Conditions
post-cardiac arrest syndrome (PCAS)brain ischemia
Beyond the preview
Go deeper on jRCTs031180352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180352.